// App-Quantinova.ai

: Implication of Hypoxia-Inducible Factor-1 (HIF-1) As a New Therapeutic Target in JAK2V617F Positive Myeloproliferative Neoplasms (MPN)

Researchers

Presenter

  • Julian Baumeister

Principal Investigators

  • Nicolas Chatain

  • Annika Hubrich

  • Caroline Kstermann

  • Stephanie Sontag

  • Kristin Ser

  • Martin Zenke

  • Tim H Brmmendorf

  • Kamil Kranc

  • Steffen Koschmieder

  • Deniz Gezer

Medical Centers

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

  • Institute of Biomedical Engineering, Department of Cell Biology, RWTH Aachen University Medical School, 52074 Aachen, RWTH Aachen University, Aachen, Germany

  • Institute for Biomedical Engineering, Department of Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

  • Medical Research Council Institute of Genetics and Molecular Medicine, Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom

  • Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, RWTH Aachen University Hospital, Aachen, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Chronic Myelogenous Leukemia

  • Polycythemia vera

  • Myelofibrosis

Biomarkers

  • Breakpoint Cluster Region

  • Peripheral blood mononuclear cell

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Proto-oncogene tyrosine-protein kinase ROS

  • Hypoxia-inducible factor-1

  • Serine/threonine-protein kinase mTOR

  • Signal transducer and activator of transcription 5

  • Vascular endothelial growth factor A

  • PI3K/AKT

Drug/Treatment

  • Echinomycin

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved